Trading was light with 186K shares changing hands on Tuesday. Volume was down 82.71% under the stocks average daily volume.
Traders are more bullish on the company lately if you take into consideration the change in short interest. The firm saw a fall in short interest of -10.65% as of the latest report on October 13, 2017. Short interest fell 136,968 over that period. Days to cover decreased from 5.0 to 1.0 and the short interest percentage is 0.04% as of October 13.
A few notable investment firms have updated their holdings. Bank Of NEW York Mellon Corp bolstered its ownership by buying 16,077 shares an increase of 601.9% from 03/31/2017 to 06/30/2017. Bank Of NEW York Mellon Corp claims 18,748 shares valued at $14,000. The total value of its holdings increased 600.0%. As of quarter end Citadel Advisors LLC had acquired a total of 5,890 shares growing its position 17.0%. The value of the investment in TENX increased from $19,000 to $30,000 a change of $11,000 quarter to quarter.
Creative Planning augmented its stake by buying 1,000 shares an increase of 100.0% as of 06/30/2017. Creative Planning controls 2,000 shares worth $1,000. The value of the position overall is down by 0.0%. As of the end of the quarter Tower Research Capital LLC (trc) had bought 11,762 shares growing its holdings by 916.0%. The value of the total investment in Tenax Therapeutics, Inc. went from $3,000 to $10,000 increasing 233.3% for the reporting period.
The company is trading down by 8.51% since yesterday’s close of $0.43. The stock last traded at $0.43 marginally over $0.41, the stock’s 50 day moving average and which is well below the 200 day moving average of $0.48. The 50 day moving average was up by +5.36% whereas the 200 day average was down by -10.88%.
As of the latest earnings report the EPS was $-1.43 and is estimated to be $-0.36 for the current year with 28,236,000 shares now outstanding. Analysts expect next quarter’s EPS will be $-0.08 with next year’s EPS anticipated to be $-0.28.
Tenax Therapeutics, Inc., launched on April 17, 2008, is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Business’s main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure. Levosimendan represents therapeutic modalities for the treatment of Low Cardiac Output Syndrome (LCOS), septic shock and other critical care conditions..